Clinical trial
A Phase I, Open-label, Drug Interaction Study to Evaluate the Effect of a Single-dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Subjects With Rheumatoid Arthritis
NCT01636557 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Open-label, Drug Interaction Study to Evaluate the Effect of a Single-dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Subjects With Rheumatoid Arthritis
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 11, 2012
- Completion date
- October 19, 2013
- Enrollment
- 12 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.